Pablo Santamarina-Ojeda

Dr. Pablo Santamarina-Ojeda

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2019 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
RPRaúl Pérez
Raúl Pérez
PSPablo Santamarina-Ojeda
Pablo Santamarina-Ojeda
JTJuan Ramón Tejedor
Juan Ramón Tejedor
RURocio Urdinguio
Rocio Urdinguio
Julio Alvarez PittiJulio Alvarez Pitti
Julio Alvarez Pitti
Empar LurbeEmpar Lurbe
Empar Lurbe
Early life is a period of drastic epigenetic remodeling in which the epigenome is especially sensitive to extrinsic and intrinsic influence. However, the epigenome-wide dynamics of the DNA methylation changes that occur during this period have not been sufficiently characterized in longitudinal studies. To this end, we studied the DNA methylation status of more than 750,000 CpG sites using Illumina MethylationEPIC arrays on 33 paired blood samples from 11 subjects at birth and at 5 and 10 years of age, then characterized the chromatin context associated with these loci by integrating our data with histone, chromatin-state and enhancer-element external datasets, and, finally, validated our results through bisulfite pyrosequencing in two independent longitudinal cohorts of 18 additional subjects. We found abundant DNA methylation changes (110,726 CpG sites) during the first lustrum of life, while far fewer alterations were observed in the subsequent 5 years (460 CpG sites). However, our analysis revealed persistent DNA methylation changes at 240 CpG sites, indicating that there are genomic locations of considerable epigenetic change beyond immediate birth. The chromatin context of hypermethylation changes was associated with repressive genomic locations and genes with developmental and cell signaling functions, while hypomethylation changes were linked to enhancer regions and genes with immunological and mRNA and protein metabolism functions. Significantly, our results show that genes that suffer simultaneous hyper- and hypomethylation are functionally distinct from exclusively hyper- or hypomethylated genes, and that enhancer-associated methylation is different in hyper- and hypomethylation scenarios, with hypomethylation being more associated to epigenetic changes at blood tissue-specific enhancer elements. These data show that epigenetic remodeling is dramatically reduced after the first 5 years of life. However, there are certain loci which continue to manifest DNA methylation changes, pointing towards a possible functionality beyond early development. Furthermore, our results deepen the understanding of the genomic context associated to hyper- or hypomethylation alterations during time, suggesting that hypomethylation of blood tissue-specific enhancer elements could be of importance in the establishment of functional states in blood tissue during early-life.

18 June 2019 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
ACAntonella Carella
Antonella Carella
JTJuan R. Tejedor
Juan R. Tejedor
MGMaría G. García
María G. García
RURocio Urdinguio
Rocio Urdinguio
GBGustavo F. Bayón
Gustavo F. Bayón
MFMario Fdez. Fraga
Mario Fdez. Fraga
Loss of 5‐hydroxymethylcytosine (5hmC) has been associated with mutations of the ten–eleven translocation (TET) enzymes in several types of cancer. However, tumors with wild‐type TET genes can also display low 5hmC levels, suggesting that other mechanisms involved in gene regulation might be implicated in the decline of this epigenetic mark. Here we show that DNA hypermethylation and loss of DNA hydroxymethylation, as well as a marked reduction of activating histone marks in the TET3 gene, impair TET3 expression and lead to a genome‐wide reduction in 5hmC levels in glioma samples and cancer cell lines. Epigenetic drugs increased expression of TET3 in glioblastoma cells and ectopic overexpression of TET3 impaired in vitro cell growth and markedly reduced tumor formation in immunodeficient mice models. TET3 overexpression partially restored the genome‐wide patterns of 5hmC characteristic of control brain samples in glioblastoma cell lines, while elevated TET3 mRNA levels were correlated with better prognosis in glioma samples. Our results suggest that epigenetic repression of TET3 might promote glioblastoma tumorigenesis through the genome‐wide alteration of 5hmC.

28 June 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ORObdulia Rabal
Obdulia Rabal
EJEdurne San José-Enériz
Edurne San José-Enériz
XAXabier Agirre
Xabier Agirre
JSJuan Antonio Sánchez-Arias
Juan Antonio Sánchez-Arias
AVAmaia Vilas-Zornoza
Amaia Vilas-Zornoza
JOJulen Oyarzabal
Julen Oyarzabal

18 February 2021 in Blood
Verified
Journal Article
Open access
PDF file
RERosaura Esteve-Puig
Rosaura Esteve-Puig
FCFina Climent
Fina Climent
DPDavid Piñeyro
David Piñeyro
EDEva Domingo-Domenech
Eva Domingo-Domenech
VDVerónica Dávalos
Verónica Dávalos
MEManel Esteller
Manel Esteller

25 May 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
MGMaría G. García
María G. García
ACAntonella Carella
Antonella Carella
RURocio Urdinguio
Rocio Urdinguio
GBGustavo F. Bayón
Gustavo F. Bayón
VLVirginia Lopez
Virginia Lopez
MFMario Fdez. Fraga
Mario Fdez. Fraga
Epigenetic dysregulation of TET2 in human glioblastoma Epigenetic dysregulation of TET2 in human glioblastoma

29 March 2019 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
RURocio Urdinguio
Rocio Urdinguio
VLVirginia Lopez
Virginia Lopez
GBGustavo F Bayón
Gustavo F Bayón
RGRafael Diaz de la Guardia
Rafael Diaz de la Guardia
MSMarta I Sierra
Marta I Sierra
MFMario Fdez. Fraga
Mario Fdez. Fraga
Histone H4 acetylation at Lysine 16 (H4K16ac) is a key epigenetic mark involved in gene regulation, DNA repair and chromatin remodeling, and though it is known to be essential for embryonic development, its role during adult life is still poorly understood. Here we show that this lysine is massively hyperacetylated in peripheral neutrophils. Genome-wide mapping of H4K16ac in terminally differentiated blood cells, along with functional experiments, supported a role for this histone post-translational modification in the regulation of cell differentiation and apoptosis in the hematopoietic system. Furthermore, in neutrophils, H4K16ac was enriched at specific DNA repeats. These DNA regions presented an accessible chromatin conformation and were associated with the cleavage sites that generate the 50 kb DNA fragments during the first stages of programmed cell death. Our results thus suggest that H4K16ac plays a dual role in myeloid cells as it not only regulates differentiation and apoptosis, but it also exhibits a non-canonical structural role in poising chromatin for cleavage at an early stage of neutrophil cell death.